89 related articles for article (PubMed ID: 8485022)
1. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.
Rolan PE; Parker JE; Gray SJ; Weatherley BC; Ingram J; Leavens W; Wootton R; Posner J
Br J Clin Pharmacol; 1993 Apr; 35(4):419-25. PubMed ID: 8485022
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.
Rolan PE; Mercer AJ; Wootton R; Posner J
Br J Clin Pharmacol; 1995 Apr; 39(4):375-80. PubMed ID: 7640143
[TBL] [Abstract][Full Text] [Related]
3. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia.
Arya R; Rolan PE; Wootton R; Posner J; Bellingham AJ
Br J Haematol; 1996 Jun; 93(4):817-21. PubMed ID: 8703810
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.
Keidan AJ; Sowter MC; Johnson CS; Marwah SS; Stuart J
Clin Sci (Lond); 1989 Apr; 76(4):357-62. PubMed ID: 2714049
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
[TBL] [Abstract][Full Text] [Related]
6. Substituted benzaldehydes (12C79 and 589C80) that stabilize oxyhaemoglobin also protect sickle cells against calcium-mediated dehydration.
Stone PC; Nash GB; Stuart J
Br J Haematol; 1992 Jul; 81(3):419-23. PubMed ID: 1390217
[TBL] [Abstract][Full Text] [Related]
7. Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers.
Peck RW; Wootton R; Wiggs R; Layton G; Posner J
Br J Clin Pharmacol; 1998 Jul; 46(1):83-6. PubMed ID: 9690954
[TBL] [Abstract][Full Text] [Related]
8. The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve.
Fitzharris P; McLean AE; Sparks RG; Weatherley BC; White RD; Wootton R
Br J Clin Pharmacol; 1985 Apr; 19(4):471-81. PubMed ID: 3994894
[TBL] [Abstract][Full Text] [Related]
9. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
[TBL] [Abstract][Full Text] [Related]
10. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
Stangier J; Su CA; Roth W
J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
[TBL] [Abstract][Full Text] [Related]
12. In vitro immunomodulatory properties of tucaresol in HIV infection.
Clerici M; Cogliati M; Rizzardini G; Colombo F; Fossati S; Rhodes J; Bray D; Piconi S
Clin Immunol; 2000 Dec; 97(3):211-20. PubMed ID: 11112360
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
14. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
Bramer SL; Forbes WP; Mallikaarjun S
Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers.
Stangier J; Su CA; Schöndorfer G; Roth W
J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1355-64. PubMed ID: 11185634
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice.
Iyamu WE; Lian L; Asakura T
Chemotherapy; 2001; 47(4):270-8. PubMed ID: 11399864
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
